Nothing Special   »   [go: up one dir, main page]

MX2021002500A - Anticuerpos y secuencias de nucleotidos novedosos, y sus usos. - Google Patents

Anticuerpos y secuencias de nucleotidos novedosos, y sus usos.

Info

Publication number
MX2021002500A
MX2021002500A MX2021002500A MX2021002500A MX2021002500A MX 2021002500 A MX2021002500 A MX 2021002500A MX 2021002500 A MX2021002500 A MX 2021002500A MX 2021002500 A MX2021002500 A MX 2021002500A MX 2021002500 A MX2021002500 A MX 2021002500A
Authority
MX
Mexico
Prior art keywords
antibody molecules
nucleotide sequences
novel antibodies
ctla
viruses
Prior art date
Application number
MX2021002500A
Other languages
English (en)
Inventor
Ingrid Teige
Linda Mårtensson
Björn Frendéus
Monika Semmrich
Petra Holmkvist
Jean- Baptiste Marchand
Nathalie Silvestre
Original Assignee
Bioinvent Int Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioinvent Int Ab filed Critical Bioinvent Int Ab
Publication of MX2021002500A publication Critical patent/MX2021002500A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen moléculas de anticuerpo anti-CTLA-4 novedosas y secuencias de nucleótidos y vectores de expresión, tales como virus, que codifican tales moléculas de anticuerpo; las moléculas de anticuerpo novedosas son moléculas de anticuerpo que disminuyen Treg y tienen un efecto de disminución mejorado en las células positivas a CTLA-4, tales como Treg, en comparación con ipilimumab; también se describe el uso de dichas moléculas de anticuerpos o secuencias de nucleótidos o virus en medicina, tal como en el tratamiento del cáncer, tal como tumores sólidos.
MX2021002500A 2018-09-03 2019-09-03 Anticuerpos y secuencias de nucleotidos novedosos, y sus usos. MX2021002500A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18192311.1A EP3617230A1 (en) 2018-09-03 2018-09-03 Novel antibodies and nucleotide sequences, and uses thereof
PCT/EP2019/073488 WO2020049001A1 (en) 2018-09-03 2019-09-03 Novel antibodies and nucleotide sequences, and uses thereof

Publications (1)

Publication Number Publication Date
MX2021002500A true MX2021002500A (es) 2021-08-11

Family

ID=63490358

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002500A MX2021002500A (es) 2018-09-03 2019-09-03 Anticuerpos y secuencias de nucleotidos novedosos, y sus usos.

Country Status (11)

Country Link
US (1) US20220041723A1 (es)
EP (2) EP3617230A1 (es)
JP (2) JP7515461B2 (es)
KR (1) KR20210055722A (es)
CN (1) CN112912398B (es)
AU (1) AU2019333862A1 (es)
BR (1) BR112021003916A2 (es)
CA (1) CA3111153A1 (es)
IL (1) IL281198A (es)
MX (1) MX2021002500A (es)
WO (1) WO2020049001A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107208069A (zh) * 2014-07-16 2017-09-26 特兰斯吉恩股份有限公司 用于表达免疫检查点调节因子的溶瘤病毒
TW202321458A (zh) * 2021-09-22 2023-06-01 瑞典商生物創新國際公司 新穎抗體組合及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2123001T5 (es) 1991-06-27 2009-04-16 Bristol-Myers Squibb Company Receptor ctl4a, proteinas de fusion que lo contienen y sus usos.
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
EP3553085A1 (en) 1998-12-23 2019-10-16 Pfizer Inc Human momoclonal antibodies to ctla-4
CA2589418A1 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
EP2029756B1 (en) 2006-06-20 2016-11-09 Transgene S.A. Process for producing poxviruses and poxvirus compositions
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
AU2008250596C1 (en) 2007-05-14 2010-11-25 Bavarian Nordic A/S Purification of Vaccinia virus- and recombinant Vaccinia virus-based vaccines
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
CN101868474B (zh) 2007-11-19 2014-03-05 特朗斯吉有限公司 痘病毒溶瘤载体
AU2009214768B2 (en) 2008-02-12 2015-01-22 Sanofi Pasteur Limited Methods using ion exchange and gel filtration chromatography for poxvirus purification
SG176554A1 (en) 2009-05-12 2012-01-30 Transgene Sa Method for orthopoxvirus production and purification
GB201020995D0 (en) * 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
JP6243333B2 (ja) 2011-08-05 2017-12-06 シラジェン バイオセラピューティクス インコーポレイテッド ワクシニアウィルスの生成のための方法および組成物
EP2912063A1 (en) 2012-10-23 2015-09-02 Bristol-Myers Squibb Company Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
CN107208069A (zh) * 2014-07-16 2017-09-26 特兰斯吉恩股份有限公司 用于表达免疫检查点调节因子的溶瘤病毒
US10196445B1 (en) * 2015-03-17 2019-02-05 Bristol-Myers Squibb Company Ipilimumab variant with enhanced ADCC
PL3389699T3 (pl) * 2015-12-15 2024-07-22 OncoC4, Inc. Chimeryczne i humanizowane przeciwciała monoklonalne przeciwko ludzkiemu ctla4 i ich zastosowania
EP3400023A1 (en) * 2016-01-10 2018-11-14 ModernaTX, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
NL2017270B1 (en) * 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
MX2019006340A (es) 2016-12-07 2019-11-07 Agenus Inc Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) y métodos de uso de los mismos.
MX2019013648A (es) * 2017-05-19 2021-01-08 Wuxi Biologics Shanghai Co Ltd Anticuerpos monoclonales novedosos para proteina 4 asociada con el linfocito t citotoxico (ctla-4).

Also Published As

Publication number Publication date
JP7515461B2 (ja) 2024-07-12
CA3111153A1 (en) 2020-03-12
EP3617230A1 (en) 2020-03-04
AU2019333862A1 (en) 2021-03-11
BR112021003916A2 (pt) 2021-05-25
CN112912398A (zh) 2021-06-04
WO2020049001A1 (en) 2020-03-12
JP2024091656A (ja) 2024-07-05
KR20210055722A (ko) 2021-05-17
EP3847193A1 (en) 2021-07-14
IL281198A (en) 2021-04-29
US20220041723A1 (en) 2022-02-10
JP2022512544A (ja) 2022-02-07
CN112912398B (zh) 2024-10-25

Similar Documents

Publication Publication Date Title
Bhatia et al. Cellular and molecular mechanisms in cancer immune escape: a comprehensive review
MX2022008184A (es) Anticuerpos anti pd-1 y anti-lag3 para usarse en el tratamiento de cancer.
WO2018183888A3 (en) Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
CR20200466A (es) Agentes anticuerpos anti-cd25
PH12019502661A1 (en) Articles of manufacture and methods for treatment using adoptive cell therapy
WO2018187613A3 (en) Anti-icos agonist antibodies and uses thereof
EA201992765A1 (ru) Белки на основе антител с привитым цитокином и способы их применения в лечении рака
MX2020006715A (es) Anticuerpos especificos del heterodimero de cd3-delta/epsilon.
Pham et al. Effects of ADAM10 and ADAM17 inhibitors on natural killer cell expansion and antibody-dependent cellular cytotoxicity against breast cancer cells in vitro
WO2019222275A3 (en) Compositions and methods for tcr reprogramming using inducible fusion proteins
NZ743124A (en) Antibodies targeting fc receptor-like 5 and methods of use
NZ750005A (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
Lucarini et al. Dendritic cells: behind the scenes of T-cell infiltration into the tumor microenvironment
PH12019500643A1 (en) Antibodies that bind interleukin-2 and uses thereof
Toffoli et al. Natural killer cells and anti-cancer therapies: reciprocal effects on immune function and therapeutic response
Schmidt et al. A killer choice for cancer immunotherapy
MX2021015317A (es) Terapia de combinacion de una terapia citotoxica mediada por celulas y un inhibidor de una proteina de la familia bcl2 de prosupervivencia.
ZA202205927B (en) Anti-yellow fever virus antibodies, and methods of their generation and use
Armitage et al. Fine-tuning the tumour microenvironment: current perspectives on the mechanisms of tumour immunosuppression
MX2021002500A (es) Anticuerpos y secuencias de nucleotidos novedosos, y sus usos.
MX2021008022A (es) Proteínas heterodiméricas para modular células t gamma delta.
Damele et al. Targeted therapies: friends or foes for patient’s NK cell-mediated tumor immune-surveillance?
MX2021015766A (es) Nuevos antigenos y metodos contra el cancer.
PH12020551453A1 (en) Anti-cd25 for tumour specific cell depletion
MX2022001781A (es) Metodos de terapia celular.